Patents Assigned to Stallergenes S.A.
-
Patent number: 9187568Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.Type: GrantFiled: May 7, 2010Date of Patent: November 17, 2015Assignee: STALLERGENES S.A.Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
-
Publication number: 20140377761Abstract: The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.Type: ApplicationFiled: September 5, 2012Publication date: December 25, 2014Applicant: STALLERGENES S.A.Inventors: Philippe Moingeon, Aline Zimmer, Julien Bouley, Laurent Mascarell, Emmanuel Nony
-
Publication number: 20140112955Abstract: The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.Type: ApplicationFiled: April 6, 2012Publication date: April 24, 2014Applicant: STALLERGENES S.A.Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Héléne Moussu, Karine Jain
-
Publication number: 20140079795Abstract: The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.Type: ApplicationFiled: November 22, 2013Publication date: March 20, 2014Applicant: STALLERGENES S.A.Inventors: Nathalie SAINT-LU, Alain RAZAFINDRATSITA, Sophie TOURDOT, Philippe MOINGEON, Laurence VAN OVERTVELT
-
Patent number: 8632993Abstract: The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.Type: GrantFiled: April 30, 2010Date of Patent: January 21, 2014Assignee: Stallergenes S.A.Inventors: Philippe Moingeon, Thierry Batard, Emmanuel Nony
-
Patent number: 8375690Abstract: A pollen harvesting machine having a motorized chassis on which there are mounted heads for harvesting pollen by suction, which heads are connected by a suction circuit to a separation cyclone, which is connected to a suction fan. The separation cyclone is associated with a pollen recovery hopper. Each head comprises an assembly of a suction hood which has a generally frustroconical portion, which widens between an upper opening which is connected to the remainder of the suction circuits of the machine, and a polygonal base.Type: GrantFiled: July 29, 2010Date of Patent: February 19, 2013Assignee: Stallergenes S.A.Inventors: Marianne LaFargue, Vincent Nicolas
-
Patent number: 8356464Abstract: A pollen harvesting machine having a motorized chassis on which there are mounted heads for harvesting pollen by suction and which heads are connected by a suction circuit to a separation cyclone which is in turn connected to a suction fan. The cyclone is associated with a pollen recovery hopper which is constructed to be cooled to freeze the harvested pollen.Type: GrantFiled: July 30, 2010Date of Patent: January 22, 2013Assignee: Stallergenes S.A.Inventors: Marianne Lafargue, Vincent Nicolas
-
Patent number: 8272162Abstract: The present invention relates to a method for preparing raw pollen which is suitable for being used for the preparation of allergen extracts. The method involves instantaneously freezing the pollen immediately after harvesting, optionally followed by drying the frozen pollen by sublimation.Type: GrantFiled: July 30, 2010Date of Patent: September 25, 2012Assignee: Stallergenes S.A.Inventor: Marianne LaFargue
-
Publication number: 20120171198Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.Type: ApplicationFiled: May 7, 2010Publication date: July 5, 2012Applicant: STALLERGENES S.A.Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
-
Publication number: 20120171710Abstract: The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.Type: ApplicationFiled: April 30, 2010Publication date: July 5, 2012Applicant: Stallergenes S.A.Inventors: Philippe Moingeon, Thierry Batard, Emmanuel Nony
-
Publication number: 20120148626Abstract: The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.Type: ApplicationFiled: June 7, 2010Publication date: June 14, 2012Applicant: STALLERGENES S.A.Inventors: Philippe Moingeon, Thierry Batard, Bertrand Villet
-
Publication number: 20110150987Abstract: The present invention relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.Type: ApplicationFiled: May 20, 2009Publication date: June 23, 2011Applicant: STALLERGENES S.A.Inventors: Nathalie Saint-Lu, Alain Razafindratsita, Sophia Tourdot, Philippe Moingeon, Laurence Van Overtvelt
-
Publication number: 20080274059Abstract: The present invention relates to fusion proteins comprising a Group I allergen and a Group II allergen from the genus Dermatophagoides, isolated nucleic acid coding for them and their use for the manufacture of a medicament to prevent or treat a mite allergic reaction.Type: ApplicationFiled: October 9, 2007Publication date: November 6, 2008Applicant: STALLERGENES S.A.Inventors: Philippe MOINGEON, Ingrid Bulder, Veronique Bordas, Laetitia Bussieres